Dr. Galsky on Biomarkers for Satraplatin in mCRPC

Matthew D. Galsky, MD
Published: Tuesday, Mar 04, 2014

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Satraplatin is an oral platinum drug that has been tested in phase III trial but did not show survival benefit and was not approved by the FDA. Galsky says that satraplatin represents a clear example of a drug that has objective evidence that it works and inhibits tumor growth but did not work in enough patients.

The question remains as to whether it’s possible to identify which patients will respond to satraplatin. In this trial, about half of the patients saw benefit with satraplatin, consistent with phase III results, and now tumor samples are being analyzed.

Matthew D. Galsky, MD, associate professor, medicine, hematology and medical oncology, assistant professor, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Satraplatin is an oral platinum drug that has been tested in phase III trial but did not show survival benefit and was not approved by the FDA. Galsky says that satraplatin represents a clear example of a drug that has objective evidence that it works and inhibits tumor growth but did not work in enough patients.

The question remains as to whether it’s possible to identify which patients will respond to satraplatin. In this trial, about half of the patients saw benefit with satraplatin, consistent with phase III results, and now tumor samples are being analyzed.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x